Peter Steyger, PhD
Peter Steyger, PhD

Peter Steyger, PhD

Clinical Professor
Director, Translational Hearing Center - Dept of Biomedical Sciences core facility
School of Medicine

Academic Appointments

Department

  • Biomedical Sciences

Position

  • Clinical Professor

Publications and Presentations

Books

  • Steyger PS. Inflammation Potentiates Cochlear Uptake of Ototoxins and Drug-Induced Hearing Loss . In: Inflammatory Mechanisms in Mediating Hearing Loss. Ramkumar V, Rybak LP, editors. Cham: Springer; 2018. Chapter 7; p.133-147. 237p.
     , Springer Publishing, 2018

Articles

  • Kros CJ, Steyger PS. Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies. Cold Spring Harb Perspect Med. 2019 Nov 1;9(11). Review. PubMed PMID: 30559254; PubMed Central PMCID: PMC6579718. http://perspectivesinmedicine.cshlp.org/content/9/11/a033548.abstract. , Perspectives in Medicine, 9(11), 2019
  • Jiang M, Li H, Johnson A, Karasawa T, Zhang Y, Meier WB, Taghizadeh F, Kachelmeier A, Steyger PS. Inflammation up-regulates cochlear expression of TRPV1 to potentiate drug-induced hearing loss. Sci Adv. 2019 Jul;5(7):eaaw1836. doi:10.1126/sciadv.aaw1836. eCollection 2019 Jul. PubMed PMID: 31328162; PubMed Central PMCID: PMC6636990. https://advances.sciencemag.org/content/5/7/eaaw1836.abstract.
     , Science Advances, Jul;5(7), 2019
  • Nyberg S, Abbott NJ, Shi X, Steyger PS, Dabdoub A. Delivery of therapeutics to the inner ear: The challenge of the blood-labyrinth barrier. Sci Transl Med. 2019 Mar 6;11(482). doi:10.1126/scitranslmed.aao0935. Review. PubMed PMID: 30842313; PubMed Central PMCID: PMC6488020. https://stm.sciencemag.org/content/11/482/eaao0935/tab-article-info., Science Translational Medicine, 11, 482, 2019
  • Adler HJ, Ratnanather JT, Steyger PS, Buran BN. Scientists with Hearing Loss Changing Perspectives in STEMM. Acoust Today. 2019 Spring;15(1):66-70. PubMed PMID: 31423114; PubMed Central PMCID: PMC6697183. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697183/
     , Acoustics Today, 15(1), 66-70, 2019
  • Kachelmeier A, Shola T, Meier WB, Johnson A, Jiang M, Steyger PS. Simplified, automated methods for assessing pixel intensities of fluorescently-tagged drugs in cells. PLoS One. 2018;13(11):e0206628. doi: 10.1371/journal.pone.0206628. eCollection 2018. PubMed PMID: 30383813; PubMed Central PMCID: PMC6211712. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211712/
     , PLoS One, 13(11), 2018
  • Garinis AC, Kemph A, Tharpe AM, Weitkamp JH, McEvoy C, Steyger PS. Monitoring neonates for ototoxicity. Int J Audiol. 2018 Sep;57(sup4):S41-S48. doi: 10.1080/14992027.2017.1339130. Epub 2017 Jun 22. Review. PubMed PMID: 28949262; PubMed Central PMCID: PMC5741535. https://www.ncbi.nlm.nih.gov/pubmed/28949262
     , 57(sup4), S41-S48, 2018

Editing and Reviews

  • Steyger PS, Cunningham L, Esquivel C, Watts K and Zuo J (2018). Editorial: Cellular Mechanisms of Ototoxicity. Front. Cell. Neurosci. 12:75. PMID: 29636663 PMCID: PMC5881100. https://doi.org/10.3389/fncel.2018.00075
     , Frontiers in Cellular Neuroscience, 2018

Presentations

  • Keynote speaker:  Otopathology of ototoxicity and noise exposure:  From animal models to audiological management, NCRAR biennial conference, Portland VA, OR, Sept 2019, 2019

Research and Scholarship

Grant Funding Received

  • NIH/NIDCD R01 DC04555 Steyger (PI) 01/11/2012 to 01/31/2021 Cochlear trafficking and hair cell uptake of aminoglycosides Specific aim: to identify the effect of systemic inflammation on aminoglycoside uptake and subsequent ototoxicity in the cochlea in vivo. Role: PI.
  • LB692 (Steyger-2019) Steyger (PI) 03/01/2019 – 06/30/2022 NTSBRDF/State of Nebraska The Mechanism, and Clinical Risk, of Drug-Induced Hearing Loss The specific aims are the setup up a new research laboratory with the following specific aims: (i) Identify the molecular mechanisms for AGs to cross the strial BLB and enter hair cells; (ii) Define the signaling pathways by which inflammation potentiates AG-induced ototoxicity; and (iii) What is the clinical risk of drug-induced hearing loss in neonates? Role: PI.
  • R01 DC016680-01A1 Steyger (PI) 07/01/2019 – 06/30/2024 NIH/NIDCD Clinical factors in aminoglycoside-induced ototoxicity Specific aims are to determine (i) if gentamicin dose-dependently increases hearing loss in infants, and (ii) verify if (suspected) sepsis potentiates gentamicin-induced hearing loss in infants. If gentamicin-induced hearing loss in NICU graduates is (i) dose-dependent, and/or (ii) potentiated by (suspected) sepsis, these data will predicate the need for ototoxicity monitoring prior to, and following, discharge from the NICU. Role: PI.

Awards and Honors

  • Keynote Speaker, NCRAR biennial conference, 2019
  • Guest Editor, Frontiers in Celluar Neuroscience, 2018
  • Lead Discussant, Hearing Center of Excellence (DOD), 2016
  • Associate Editor, Frontiers in Medicine - Translational Medicine, 2016
  • Guest Editor, Frontiers in Celluar Neuroscience, 2018